Published in

Elsevier, European Journal of Medicinal Chemistry, (152), p. 1-9, 2018

DOI: 10.1016/j.ejmech.2018.04.016

Elsevier, European Journal of Medicinal Chemistry, (146), p. 47-59, 2018

DOI: 10.1016/j.ejmech.2018.01.033

Elsevier, European Journal of Medicinal Chemistry, (142), p. 523-549, 2017

DOI: 10.1016/j.ejmech.2017.09.035

Links

Tools

Export citation

Search in Google Scholar

Discovery of BAZ2A Bromodomain Ligands

Journal article published in 2017 by Beata Żołnowska, Pavlína Řezáčová, Alice Zamagni, Bernhard Wűnsch, Nadia Zaffaroni, Shane M. Wilkinson, R. S.-M. Wong ORCID, W.-Y. Wong, Eike-Christian Wamhoff ORCID, Q.-W. Wang, Oliver Werz, Paula Carolina de Souza, Jean Leandro dos Santos, Giulio Vistoli, Sonja Visentin and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Tuberculosis (TB) remains a serious health problem responsible to cause millions of deaths annually. The scenario becomes alarming when it is evaluated that the number of new drugs does not increase proportionally to the emergence of resistance to the current therapy. Furoxan derivatives, known as nitric oxide (NO) donors, have been described to exhibit antitubercular activity. Herein, a novel series of hybrid furoxan derivatives (1,2,5-oxadiazole 2-N-oxide) (compounds 4a-c, 8a-c and 14a-c) were designed, synthesized and evaluated in vitro against Mycobacterium tuberculosis (MTB) H37Rv (ATCC 27294) and a clinical isolate MDR-TB strain. The furoxan derivatives have exhibited MIC90 values ranging from 1.03 to 62 mM (H37Rv) and 7.0e50.0 mM (MDR-TB). For the most active compounds (8c, 14a, 14b and 14c) the selectivity index ranged from 3.78 to 52.74 (MRC-5 cells) and 1.25e34.78 (J774A.1 cells). In addition, it was characterized for those compounds logPo/w values between 2.1 and 2.9. All compounds were able to release NO at levels ranging from 0.16 to 44.23%. Among the series, the phenylsulfonyl furoxan derivatives (compounds 14a-c) were the best NO-donor with the lowest MIC90 values. The most active compound (14c) was also stable at different pHs (5.0 and 7.4). In conclusion, furoxan derivatives were identified as new promising compounds useful to treat tuberculosis.